Free shipping on all orders over $ 500


Cat. No. M21191
Milvexian Structure

BMS-986177; JNJ-70033093

Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Milvexian (BMS-986177) is an orally bioavailable, reversible, direct inhibitor of human and rabbit factor (FXIa) with Ki values of 0.11 nM and 0.38 nM, respectively.

Chemical Information
Molecular Weight 626.44
Formula C28H23Cl2F2N9O2
CAS Number 1802425-99-5
Solubility (25°C) N/A
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Vidya Perera, et al. Sci Rep. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants

[2] Vidya Perera, et al. Clin Pharmacokinet. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants

[3] Jeffrey I Weitz, et al. N Engl J Med. Milvexian for the Prevention of Venous Thromboembolism

[4] Pancras C Wong, et al. J Thromb Haemost. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits

[5] Vidya Perera, et al. Clin Transl Sci. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor

Related Factor Xa Products

MK-2060 is a monoclonal antibody with dual activity to inhibit coagulation factors XI and Xia, blocking both the activation of coagulation factor XI and the downstream activity of the activated protein. It can be used in studies related to end-stage renal disease (ESRD).

Xisomab 3G3

Xisomab 3G3 is a recombinant human-derived monoclonal antibody to coagulation factor XI (F11) that blocks factor XI activation mediated by factor XIIa in a concentration-dependent manner.


FXIa-IN-13 is an Factor Xa inhibitor with antithrombotic activity.

EMD 495235

EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM.


Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa.

Abmole Inhibitor Catalog

Keywords: Milvexian, BMS-986177; JNJ-70033093 supplier, Factor Xa, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.